The filing is a financing reset, not an earnings event. UTI signed a new revolving credit agreement that will refinance certain existing debt and support working capital, corporate purposes, acquisitions, and permitted distributions (Credit agreement preamble). 〔0〕
The headline capacity is substantial, but the filing does not say UTI drew $200 million. The facility provides $200 million of total revolving commitments, with Fifth Third, JPMorgan, Truist, PNC, and Citibank participating (Annex B).
| Financing term | Filing detail |
|---|---|
| Revolving commitment | $200 million (Revolving Loan Commitment) |
| Maturity | August 12, 2031 (Commitment Termination Date) |
| Incremental debt capacity | Up to $75 million (Section 2.1(d)) |
| Acquisition basket | Up to $200 million over the facility’s life (Permitted Acquisition) |
| Maximum net leverage | 3.00x (Section 6.1) |
| Minimum interest coverage | 3.00x (Section 6.2) |
The strategic benefit is flexibility rather than immediate balance-sheet improvement. UTI can add up to $75 million of incremental revolver or term debt and has a $200 million lifetime acquisition basket, but every acquisition must preserve the financial covenants and at least $50 million of liquidity (Sections 2.1(d) and Permitted Acquisition). 〔1〕
The key limitation is that the filing gives no pricing, drawn balance, or before-and-after leverage comparison. The agreement’s fee letter is referenced but not disclosed, and the filing does not establish whether the new facility is cheaper, larger, or more restrictive than the prior 2022 credit agreement. That prevents a clean beat-or-miss call against market expectations; the best read is mixed: more strategic capacity, but no disclosed incremental cash or quantified financing benefit.
The next hard checkpoint is covenant performance after the refinancing. The first formal leverage and interest-coverage tests begin with the fiscal quarter ending September 30, 2026 (Sections 6.1, 6.2, and 7.1(c)). 〔2〕
Read the original 8-K on SEC EDGAR ↗